Clinical research
Shares of Assembly Biosciences have fallen more than 20% in premarket trading after the company discontinued the development of a hepatitis B therapeutic candidate.
Takeda said that Phase III PANTHER, which studied the effectiveness of pevonedistat for different types of leukemia, did not produce significant results in terms of event-free survival.
FDA greenlit Janssen’s Invega Hafyera, the first long-acting antipsychotic drug of its kind that provides six months’ control of symptoms with a single dose.
The study of Molnupiravir will assess 1,300 adult participants 18 and over who cohabitate with someone who has tested positive for the coronavirus and is symptomatic.
AC Immune and Genentech announced that their Phase II Lauriet trial of semorinemab in mild-to-moderate Alzheimer’s disease hit one of its co-primary endpoints.
Johnson & Johnson announced failed Imbokodo Phase IIb trial in HIV. The study evaluated the company’s investigational HIV vaccine regimen in young women in sub-Saharan Africa.
The trial will enroll about 4,000 people worldwide to confirm the drug’s safety and immunogenicity profiles.
Regeneron and Sanofi broke ground with the 2017 approval of the first biologic drug for atopic dermatitis, the most common form of eczema driven by allergic reactions.
Shares of Bone Therapeutics are down more than 34% on the Euronext stock exchange after the company announced its Phase III osteoarthritis study failed to meet primary and critical secondary endpoints.
It was a busy week for clinical trial news. Here’s a look.
PRESS RELEASES